COMPUTATIONAL APPROACH FOR DESIGNING AND DEVELOPMENT OF POTENT DRUG INHIBITOR FOR APP GENE IN ALZHEIMER’S DISEASE

Alzheimer’s disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, reasoning, planning, language, and perception, and eventually even the ability to carry out the simplest tasks. Many scientists believe that Alzheimer’s disease results from an increase in the production or accumulation of a specific protein (beta-amyloid protein) in the brain that leads to nerve cell death.The brains of people with AD have an abundance of two abnormal structures amyloid plaques and neurofibrillary tangles that are made of misfolded proteins. This is especially true in certain regions of the brain that are important in memory. In people with Alzheimer’s disease, deposits called amyloid plaques build up in the brain. These are composed, in part, of a protein called beta-amyloid, which is a fragment of the amyloid precursor protein (APP).A mutation in the gene that makes APP is believed to be responsible for 5 to 20 percent of all early onset familial Alzheimer’s disease. People with a mutation in the APP gene tend to develop Alzheimer’s disease at around age 50.The present work deals with the designing a suitable drug by molecular docking which acts on the APP gene to regulate the amyloid plagues formation in the brain.